Over the past decade, metabolism-based therapies, including the classic ketogenic diet (KD) along with pharmaceutical compounds based on this treatment, have experienced a remarkable explosion in global clinical growth and scientific research. As a result, interventional approaches based on an understanding of metabolic derangements in epileptic brain have evolved in a manner that has extended the traditional focus on diet alteration to now a broader framework more aptly termed "metabolism-based therapies." This symposium will provide a state-of-the-art update on the basic-translational science underlying all metabolism-based treatments, the co-morbidities of epilepsy that may be concurrently amenable to dietary and metabolic targeting, mounting clinical evidence and international consensus protocols for clinical implementation (particularly in the infant population), and the emerging use of the ketogenic diet in forms of refractory status epilepticus and related disorders associated with inflammatory brain disorders.
Learning Objectives
Following participation in this activity, learners should be able to:
Introduction: Eric H. Kossoff, MD
Cellular Metabolism as a Paradigm for Experimental Therapeutics in Epilepsy: Susan A. Masino, PhD
Metabolic Approaches for Treating Complications and Co-Morbidities of Epilepsy: Kristina A. Simeone, PhD
Clinical Evidence for Metabolism-Based Therapies in Children: Trials and Guidelines in 2018: Elizabeth J. Donner, MD, MSc, FRCPC
Ketogenic Diet for Infants? Results from the KIWE Study and Experience with Early Epileptic Encephalopathies: Anita May Devlin, MD, MRCP
Safety and Prevention of Risks from the Use of Metabolism-based Therapies: Robyn Blackford, RD, LDN
Are there Anti-Inflammatory Effects of Metabolic Treatments? Lessons from Refractory Status Epilepticus: Stephane Auvin, MD, PhD
Conclusions: Jong M. Rho, MD
Q&A and Panel Discussion
- Identify the key mechanisms thought to underlie the anti-seizure effects of the ketogenic diet
- Appreciate how metabolic substrates and enzymes have rapidly become targets for experimental therapeutics and clinical development
- Gain insights into the potential protective role of metabolism-based treatments against epilepsy co-morbidities such as SUDEP, sleep disorders, and autism spectrum disorder
- Summarize and begin implementing evidence-based and expert opinion-guided protocols for successful and safe administration of ketogenic diets and its variants
- Identify and treat patients with early-infantile epileptic encephalopathies who are candidates for metabolic treatments
- Describe how the ketogenic diet has been used in the treatment of refractory status epilepticus and epilepsies arising from brain inflammation
Program
Co-chairs: Eric H. Kossoff, MD, and Jong M. Rho, MDIntroduction: Eric H. Kossoff, MD
Cellular Metabolism as a Paradigm for Experimental Therapeutics in Epilepsy: Susan A. Masino, PhD
Metabolic Approaches for Treating Complications and Co-Morbidities of Epilepsy: Kristina A. Simeone, PhD
Clinical Evidence for Metabolism-Based Therapies in Children: Trials and Guidelines in 2018: Elizabeth J. Donner, MD, MSc, FRCPC
Ketogenic Diet for Infants? Results from the KIWE Study and Experience with Early Epileptic Encephalopathies: Anita May Devlin, MD, MRCP
Safety and Prevention of Risks from the Use of Metabolism-based Therapies: Robyn Blackford, RD, LDN
Are there Anti-Inflammatory Effects of Metabolic Treatments? Lessons from Refractory Status Epilepticus: Stephane Auvin, MD, PhD
Conclusions: Jong M. Rho, MD
Q&A and Panel Discussion